Parsonex Advisory Services’s AstraZeneca AZN Stock Holding History

Parsonex Advisory Services’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,046	Closed	-$206K	–	52
2026 Q1	$206K	Sell	1,046 -876	-46%	-$169K	0.2%	55
2025 Q4	$353K	Sell	1,922 -393	-17%	-$68.9K	0.23%	67
2025 Q3	$355K	Sell	2,315 -25	-1%	-$3.78K	0.24%	69
2025 Q2	$327K	Buy	+2,340	New	+$328K	0.27%	74

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Parsonex Advisory Services's AZN Position: Q2 2026 in Review

Parsonex Advisory Services sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 1,046 shares — an estimated $206K sold.

Parsonex Advisory Services first reported a position in AZN in Q2 2025 and held it in 4 quarters. The position peaked at $355K in Q3 2025. 1,494 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Parsonex Advisory Services reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
Parsonex Advisory Services sold 1,046 AstraZeneca shares in Q2 2026, an estimated $206K.
Parsonex Advisory Services first reported a position in AstraZeneca in Q2 2025 and held it in 4 quarters.
Parsonex Advisory Services's AstraZeneca position peaked at $355K in Q3 2025.
1,494 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Parsonex Advisory Services's 13F filing for Q2 2026, filed 10 Aug 2026.